Therapeutic area intelligence for Continuous Glucose Monitoring with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

FDA →

SAVA →

Recent signals(2)

CompetitiveJuly 2, 2026

SAVA Technologies initiates pilot trial for Continuous Glucose Monitor in Type 1 Diabetes

SAVA Technologies is conducting a pilot study to evaluate the safety and performance of its Continuous Glucose Monitor in adults with Type 1 Diabetes.

RegulatoryJune 22, 2026

FDA Approves First OTC Continuous Glucose Monitor for Children

The FDA has cleared Dexcom Inc.'s Stelo Glucose Biosensor System as the first OTC continuous glucose monitor for children aged two and older.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.